AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Repeated CBD Administration and Cannabis Outcomes

RecruitingEARLY Phase 1Ages 18 Years - 55 YearsAllHannah Harris
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * English-speaking, literate adults, * Male or female, * Between the ages of 18-55, * Body Mass Index from 18.5-32.0 kg/m2, * Not currently seeking treatment for cannabis or drug use, * Able to provide written informed consent and perform all study procedures, * If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method), * Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and * Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries. Exclusion Criteria: * Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management, * Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]), * Current or past history of major psychiatric disorder that would limit ability to participate in the study, * Use of cannabis exclusively for medical reasons (no recreational use reported), * Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours), * Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers, * Clinically significant abnormal ECG (as determined by study physician/cardiologist), * Clinically significant abnormal laboratory findings, * History of seizure disorder, * Clinically significant history of head injuries requiring medical management or long lasting sequalae, and * Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).
๐Ÿ’Š

What it tests

  • Cannabidiol, Medium Dose
  • Cannabidiol, Higher Dose
  • Active Inhaled Cannabis
  • Placebo Cannabidiol
  • Placebo Inhaled Cannabis
๐Ÿ“

Where

1 site
University of Kentucky
Lexington, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy